In the serum validation analysis, S100A9 levels were significantly elevated in the serum of both COPD and NAFLD patients, supporting its potential as a systemic inflammatory biomarker. This evidence concerns the gene S100A9 and metabolic dysfunction-associated steatotic liver disease.